Pharmacological inhibition of the Chk1 and Chk2 checkpoint kinases as well as the Notch pathway (by gamma-secretase inhibitors) has been shown to overcome the radioresistance of CD133+ glioma cells, suggesting possible therapeutic targets [112, 113]. Here, PROM1 is linked to glioma.